Insider Analysis: Kantar Health On Optimizing Indian Cancer Patient Assistance Programs For Maximum Impact
This article was originally published in PharmAsia News
With a rapidly rising cancer burden but the high costs of new targeted therapies remaining out of reach for many, India has seen the increasing adoption of company-backed patient assistance programs, or PAPs, to support access to effective treatments. But what is the best approach? Kantar Health’s Gauri Pathak and Neesha Suvarna look at the issues.
You may also be interested in...
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.